Therapeutic Advances in Hematology
Journal Highlights
- Launched in 2010.
- Gold open access journal – all articles are made freely available online immediately upon publication.
- Robust peer review.
- Listed in PubMed and indexed in Scopus and Science Citation Index Expanded (SCIE).
- Over 200,000 full-text article views annually.
Therapeutic Advances in Hematology (TAH) is a peer-reviewed open access journal which focuses on delivering the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. Please see the Aims and Scope tab for further information.
The journal is a member of the Committee on Publication Ethics (COPE).
This journal flipped to open access on July 1, 2018.
Diversity, Equity and Inclusion Statement
TAH promotes inclusive, open science that reflects the disciplinary, human, and geographic diversity of the hematology community.
Diversity as a core value embodies inclusiveness, mutual respect, and multiple perspectives.
We welcome editors, editorial board members, peer reviewers and authors from all backgrounds, cultures, ethnicities, nationalities, races, religions, sexes, sexual orientations, gender identities, mental or physical (dis)abilities, ages, career stages, socio-economic status or any other individual status.
We are committed to continually improving our editorial and review processes whilst playing our part in eradicating bias and inequality in all forms.
Submission information
Submit your manuscript today at http://mc.manuscriptcentral.com/tah.
Please see the Submission Guidelines tab for more information on how to submit your article to the journal.
Open access information
Unsolicited manuscripts submitted to TAH are subject to an article processing charge (APC) of $2,800 USD (+VAT where applicable) payable upon acceptance. The article processing charge for Plain Language Summary is $4500 USD. These articles will be published under a Creative Commons license and will be made openly available.
The APC is payable when a manuscript is accepted after peer review, before it is published. The APC is subject to taxes where applicable. Please see further details here.
Contact
Please direct any enquiries to Alex.Baliani@sagepub.co.uk.
This journal changed its publication mode from subscription to open access in 2019.
Therapeutic Advances in Hematology delivers the highest quality peer-reviewed open access original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of blood disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in hematology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.
The journal is dedicated to publishing clinical research. We do not publish preclinical research, including basic laboratory research and animal studies.
Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable.
The journal adheres to a single-anonymised peer review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; online publication is usually within three weeks of Acceptance.
| Elisabetta Abruzzese, MD, PhD | S. Eugenio Hospital, Tor Vergata University, Rome, Italy |
| Cedric Hermans, MD, PhD, FRCP (Lon, Edin) | St-Luc University Hospital, Brussels, Belgium |
| Elias Jabbour, MD | M.D. Anderson Cancer Center, Houston, TX, USA |
| Wojciech Jurczak, MD, PhD | Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland |
| Michaela Liedtke, MD | Stanford Cancer Institute, Stanford, CA, USA |
| Sarah Tasian, MD | Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA |
| Raymona Lawrence, CDE, MPH, DrPH | Georgia Southern University, USA |
| Pratima Chowdary, MD, FRCPath | Royal Free Hospital NHS Foundation Trust, London, UK |
| Graham Collins, MD, PhD | Oxford University Hospitals, Oxford, UK |
| Jorge Cortes, MD | M.D. Anderson Cancer Center, Houston, TX, USA |
| Myron Czuczman, MD | Citius Pharmaceuticals, Inc., Cranford, NJ, United States |
| Christopher Edwards, PhD | North Carolina Central University, USA |
| Elliot Epner, MD | CompHealth, United States |
| Alessandra Ferrajoli, MD | M.D. Anderson Cancer Center, Houston, TX, USA |
| Guillermo Garcia-Manero, MD | M.D. Anderson Cancer Center, Houston, TX, USA |
| Amy Geddis, MD, PhD | Seattle Children’s Hospital, Washington, WA, USA |
| David Gómez-Almaguer, MD, FACP | Universidad Autónoma de Nuevo León: San Nicolás De Los Garza, Nuevo León, Mexico |
| Katharina Gotze, MD | Technical University of Munich, Munich, Germany |
| Eric Grabowski, MD, ScD | Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA |
| Elizabeth Hexner, MD, MSTR | Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA |
| Ulrich Keller, MD | Technical University of Munich, Munich, Germany |
| Karl-Anton Kreuzer | University of Cologne, Germany |
| Hillard Lazarus, MD, FACP | Case Western Reserve University, Cleveland, OH, USA |
| Georg Lenz, MD | University Hospital Münster, Münster, Germany |
| Howard Liebman, MD | University of Southern California - Keck School of Medicine, Los Angeles, CA, USA |
| Eduardo Olavarria, MD, PhD | Imperial College London at hammersmith Hospital, London, UK |
| Johnny N. Mahlangu, MMed, FCPath, MBBCh, BSc | University of the Witwatersrand and National Health Laboratory Service, Johannesburg, South Africa |
| Pier Mannuccio Mannucci, MD | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy |
| Keith McCrae, MD | Case Western Reserve University, Cleveland Clinic, Cleveland, OH, USA |
| Neha Mehta-Shah, MD | Washington University Medical School, St. Louis, MO, USA |
| Guillermo Montalban Bravo, MD | University of Texas,MD Anderson Cancer Center, Houston, TX, USA |
| Stephen Oh | Washington University School of Medicine, St. Louis, MO, USA |
| Ifeyinwa Osunkwo, Md, MPH | Emory University School of Medicine, Atlanta, USA |
| Gaël Roué, PhD | Josep Carreras Leukaemia Research Institute (IJC), Barcelona, Spain |
| Bipin Savani | Vanderbilt University Medical Center, Nashville, TN, USA |
| Raymond SM Wong, MD, MRCP, FHKCP, FHKAM, MBChB | The Chinese University of Hong Kong (CUHK), Hong Kong, CN |
| Priya Sriskandarajah, MBBS BSc MRCP PhD FRCPath | Guy's and St Thomas' NHS Foundation Trust, London, UK |
| Peter Valent, MD | Medical University of Vienna, Vienna, Austria |
| Alessandro Vannucchi, MD | University of Florence, Florence, Italy |
| Nikolas von Bubnoff, MD | Freiburg University Medical Center, Freiburg, Germany |
| Jianxiang Wang, MD | Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China |
| Guy Young, MD | University of Southern California-Keck School of Medicine, Los Angeles, CA, USA |
| Bushra Mahdi | Sage Publications Ltd, United Kingdom |
| Daniel Diaz, PhD | Universidad Nacional Autónoma de México,Mexico City, Mexico |
| Massimo Milani, MD | MedicalDepartment, Cantabria Labs Difa Cooper, Caronno, VA, Italy |
| Elisabetta Petracci, PhD | Istituto scientifico Romagnolo per lo Studio e la Cura dei tumori (IRST) IRCCS, Meldola, Italy |
| Andrea Ripoli, PhD | Fondazione Toscana Gabriele Monasterio, Pisa, Italy |
| Tim Spelman, MBBS, PhD, BSc | Burnet Institute, Melbourne, Australia |
| David Akhavan ,MD,PhD | University of Kansas Hospital, USA |
| Ibrahim Aldos, MD | City of Hope National Cancer Center, Duarte, California, USA |
| Cecilia Arana Yi, MD, MSHS | Mayo Clinic Arizona, USA |
| Aisha Arshad, PhD. | Dr. Essa Laboratory and Diagnostic Centre, Karachi, Pakistan |
| Chieh-Lung Cheng, MD, PhD | National Taiwan University Hospital, Taipei, Taiwan |
| Dr. Perla Colunga-Pedraza, MD | Universidad Autónoma de Nuevo León, Hospital Universitario Dr. José E. González |
| Chun Yew Fong ,MBBS, BMedSci, FRACP, FRCPA, PhD | Austin Health, Melbourne, Victoria, Australia |
| Harinder Gill, MBBS, MD, FRCP, FRCPath | The University of Hong Kong, Hong Kong |
| Talal Hilal, MD | Mayo Clinic, Phoenix, Arizona, USA |
| Sebastian Klobuch ,MD | Netherlands Cancer Institute, The Netherlands |
| ZhaoYun Liu, MD | Tianjin Medical University, China |
| Yazan F. Madanat, MD | UT Southwestern Medical Center, Dallas, TX, USA |
| Azusa Nagao, MD, PhD, MSc | Kansai Medical University Hospital, Osaka, Japan |
| Davide Nappi, MD | Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS |
| Ifeyinwa Obiorah, MD, PhD | University of Virginia Health, US |
| Nikolaos Papadantonakis ,MD, Msc, PhD | Winship Cancer Institute of Emory University, Atlanta, GA, USA |
| Hemant S. Murthy, MD | Mayo Clinic Comprehensive Cancer Center, Florida, US |
| Daulath Singh, MD | Mission Cancer + Blood, Des Moines, Iowa, USA |
| Tomasz Jerzy Slebioda, PhD | Medical University of Gdansk, Poland |
| Dr. Dongdong Zhang, PhD | Xiangyang No.1 People's Hospital, Hubei University of Medicine, China |
| Ashwini Navnath Nikam | Sage Publications Ltd, India |
| Nidhi Manori | Sage Publications Ltd, India |
Manuscript submission guidelines can be accessed on Sage Journals.